Hume Health Band and Pod: what the ads claimed, and why the UK's advertising regulator found them misleading

Four Hume Health ads seen in January 2026 made health claims for two of its devices: the Hume Health Band, a wearable health tracker, and the Hume Health Pod, a set of smart scales, as the UK regulator that ruled on the ads describes them. One, a Facebook ad, called the band "YOUR 2026 STROKE DETECTOR" and said more than 1.2 million users relied on it; a YouTube ad said over a million people tracked their health daily with the Pod. On June 17, 2026, the Advertising Standards Authority (ASA), which describes itself as the UK's independent advertising regulator, upheld complaints against all four ads. This review sets the main claims against that ruling and against US regulator records.

The claims

What the ASA found

Hume Health did not respond to the ASA's inquiries, which the regulator treated as a breach of the advertising code in itself. It then upheld all three issues raised by two complainants.

First, the ads made medical claims. Under the UK code, a product may claim to diagnose, treat or prevent disease only if it has the right authorization; for a device, that means the applicable conformity marking and registration with the Medicines and Healthcare products Regulatory Agency (MHRA). The ASA said it understood that neither product was registered with the MHRA and that it had seen no evidence of the marking.

Second, three of the four ads discouraged essential treatment. The ASA said stroke, diabetes and heart disease are conditions for which qualified medical advice should be sought, and that the ads presented the devices as able to flag or predict them outside medical supervision. The ad in which a woman said the band had "saved my life", and that tests later found her main artery "85% blocked", was among those it cited.

Third, the ads exaggerated what the devices do. The ASA understood the Pod to be smart scales and the Band a wearable health tracker or smartwatch, product types it said are generally used to measure and estimate things such as weight, body composition and movement. It had seen no evidence that either could give health data at the level of detail or accuracy the ads claimed. The ads must not appear again in their current form, and the ASA referred the matter to the compliance team of the Committee of Advertising Practice (CAP), its sister organization, which writes the advertising codes.

The claims against US records

On November 11, 2026, we searched the 510(k) records in openFDA, the FDA's open data service, for an applicant named Hume and found none. That search covers only 510(k) records. It would not show an authorization the FDA granted any other way, or a device filed under another company's name, so it shows only that we found no 510(k) record under Hume's name, not that the devices lack FDA authorization.

The FDA's general wellness guidance, issued in its current form on January 6, 2026, says the FDA does not intend to examine low-risk general wellness products for compliance with device rules such as premarket review. It also says a product falls outside that category if its labeling or advertising refers to specific diseases or claims medical or clinical grade. On our reading, wording such as "STROKE DETECTOR" and "Medical-grade monitoring" is the kind the guidance describes; that is not an FDA finding, and the only FDA records we searched for Hume were its 510(k) data.

The Federal Trade Commission's guidance on health product advertising, published by its staff in December 2022, sets the standard US advertisers are expected to meet: health claims need "competent and reliable scientific evidence", for which randomized controlled human trials are the most reliable form. The guidance says anecdotes about individual consumers' experiences are never enough on their own, and that testimonials cannot be used to make claims the advertiser could not substantiate directly. Several of the claims above came as customer stories.

Verdict

The headline claims in these ads, that the band detects strokes, that it monitors like an ICU, and that the scales give DEXA-level data, are unproven on the public record. Hume Health gave the ASA no evidence for them, the ASA said it had seen none, and our search of openFDA's 510(k) records found no record under Hume's name. That is not a finding that the devices are inaccurate at the everyday metrics the ASA said such products are generally used for, such as weight, body composition and movement: neither the ruling nor the FDA records test those. Price, returns and warranty were not assessed for this review. One of the ads offered a 30-day money-back guarantee on the Pod, according to the ruling.